title: Evaluation of insulin-like growth factor acid-labile subunit as a potential biomarker of effect for deoxynivalenol-induced proinflammatory cytokine expression.
abstract: Consumption of the trichothecene deoxynivalenol (DON) suppresses growth in experimental animals - an adverse effect that was used to establish the tolerable daily intake for this toxin. DON ingestion has been recently found to suppress plasma insulin-like growth factor acid-labile subunit (IGFALS), a protein essential for growth. Studies were conducted to explore the feasibility of using plasma IGFALS as a biomarker of effect for DON. In the first study, weanling mice were fed 0, 1, 2.5, 5 and 10 ppm DON and weight and plasma IGFALS determined at intervals over 9 wk. Reduced body weight gains were detectable beginning at wk 5 in the 10 ppm dose and wk 7 at the 5 ppm dose. Plasma IGFALS was significantly depressed at wk 5 in the 5 and 10 ppm groups at wk 9 in the 10 ppm group. Depressed IGFALS significantly correlated with reduced body weight at wk 5 and 9. Benchmark dose modeling revealed the BMDL and BMD for plasma IGFALS reduction were 1.1 and 3.0 ppm DON and for weight reduction were 2.1 and 4.5 ppm DON. In the second study, it was demonstrated that mice fed 15 ppm DON diet had significantly less plasma IGFALS than mice fed identical amounts of control diet. Thus DON's influence on IGFALS likely reflects the combined effects of reduced food intake as well as its physiological action involving suppressors of cytokine signaling. Taken together, these findings suggest that plasma IGFALS might be a useful biomarker for DON's adverse effects on growth.
authors.affiliation: Department of Food Science and Human Nutrition, Michigan State University, East Lansing, MI 48824-1224, USA.
authors.forename: Brenna M
authors.initials: BM
authors.lastname: Flannery
authors.forename: Chidozie J
authors.initials: CJ
authors.lastname: Amuzie
authors.forename: James J
authors.initials: JJ
authors.lastname: Pestka
mesh_terms: D000818:Animals; D019985:Benchmarking; D015415:Biomarkers / Q000097:blood; D001835:Body Weight / Q000187:drug effects; D002352:Carrier Proteins / Q000097:blood*; D016207:Cytokines / Q000235:genetics / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004435:Eating; D005240:Feasibility Studies; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D006023:Glycoproteins / Q000097:blood*; D018836:Inflammation Mediators / Q000378:metabolism*; D051379:Mice; D014255:Trichothecenes / Q000008:administration & dosage / Q000633:toxicity*
chemical_list: D015415:Biomarkers; D002352:Carrier Proteins; D016207:Cytokines; D006023:Glycoproteins; D018836:Inflammation Mediators; D014255:Trichothecenes; C075944:insulin-like growth factor binding protein, acid labile subunit; C007262:deoxynivalenol